A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding.
作者信息
Wang Yingdan, Zhan Wuqiang, Liu Jiangyan, Wang Yanqun, Zhang Xiang, Zhang Meng, Han Lin, Ma Yunping, Lu Lu, Wen Yumei, Chen Zhenguo, Zhao Jincun, Wu Fan, Sun Lei, Huang Jinghe
机构信息
Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Fifth People's Hospital, Shanghai Public Health Clinical Center, Institutes of Biomedical Sciences, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Shanghai Immune Therapy Institute, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China.
出版信息
Cell Res. 2022 Sep;32(9):862-865. doi: 10.1038/s41422-022-00684-0. Epub 2022 Jun 29.
Abstract
摘要
相似文献
1
A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding.
Cell Res. 2022 Sep;32(9):862-865. doi: 10.1038/s41422-022-00684-0. Epub 2022 Jun 29.
2
Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
J Virol. 2022 Aug 24;96(16):e0048022. doi: 10.1128/jvi.00480-22. Epub 2022 Aug 4.
3
A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
J Virol. 2022 Sep 14;96(17):e0011822. doi: 10.1128/jvi.00118-22. Epub 2022 Aug 16.
4
Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.
Virol Sin. 2022 Apr;37(2):238-247. doi: 10.1016/j.virs.2022.02.005. Epub 2022 Feb 18.
5
Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Viruses. 2021 Jul 22;13(8):1421. doi: 10.3390/v13081421.
6
A broadly neutralizing antibody inhibits SARS-CoV-2 variants through a novel mechanism of disrupting spike trimer integrity.
Cell Res. 2023 Dec;33(12):975-978. doi: 10.1038/s41422-023-00880-6. Epub 2023 Sep 27.
7
Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
J Immunol Res. 2022 Aug 31;2022:4813199. doi: 10.1155/2022/4813199. eCollection 2022.
8
Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody.
Science. 2022 Mar 4;375(6584):1048-1053. doi: 10.1126/science.abn8863. Epub 2022 Feb 8.
9
Selection and structural bases of potent broadly neutralizing antibodies from 3-dose vaccinees that are highly effective against diverse SARS-CoV-2 variants, including Omicron sublineages.
Cell Res. 2022 Jul;32(7):691-694. doi: 10.1038/s41422-022-00677-z. Epub 2022 Jun 7.
10
Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2.
Front Immunol. 2021 Aug 30;12:715464. doi: 10.3389/fimmu.2021.715464. eCollection 2021.
引用本文的文献
1
A bivalent spike-targeting nanobody with anti-sarbecovirus activity.
J Nanobiotechnology. 2025 Mar 10;23(1):196. doi: 10.1186/s12951-025-03243-y.
2
Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection.
Commun Biol. 2025 Mar 6;8(1):378. doi: 10.1038/s42003-025-07769-7.
3
Antigenic Imprinting Dominates Humoral Responses to New Variants of SARS-CoV-2 in a Hamster Model of COVID-19.
Microorganisms. 2024 Dec 14;12(12):2591. doi: 10.3390/microorganisms12122591.
4
Exploring distinct modes of inter-spike cross-linking for enhanced neutralization by SARS-CoV-2 antibodies.
Nat Commun. 2024 Dec 4;15(1):10578. doi: 10.1038/s41467-024-54746-5.
5
Therapeutic Potential of Neutralizing Monoclonal Antibodies (nMAbs) against SARS-CoV-2 Omicron Variant.
Curr Pharm Des. 2025;31(10):753-773. doi: 10.2174/0113816128334441241108050528.
6
The Inhibiting Effect of GB-2, (+)-Catechin, Theaflavin, and Theaflavin 3-Gallate on Interaction between ACE2 and SARS-CoV-2 EG.5.1 and HV.1 Variants.
Int J Mol Sci. 2024 Aug 31;25(17):9498. doi: 10.3390/ijms25179498.
7
Antibodies utilizing VL6-57 light chains target a convergent cryptic epitope on SARS-CoV-2 spike protein and potentially drive the genesis of Omicron variants.
Nat Commun. 2024 Aug 31;15(1):7585. doi: 10.1038/s41467-024-51770-3.
8
A novel nanobody broadly neutralizes SARS-CoV-2 via induction of spike trimer dimers conformation.
Exploration (Beijing). 2023 Dec 15;4(3):20230086. doi: 10.1002/EXP.20230086. eCollection 2024 Jun.
9
Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1.
Vaccines (Basel). 2024 Apr 15;12(4):417. doi: 10.3390/vaccines12040417.
10
Identification of an IGHV3-53-Encoded RBD-Targeting Cross-Neutralizing Antibody from an Early COVID-19 Convalescent.
Pathogens. 2024 Mar 23;13(4):272. doi: 10.3390/pathogens13040272.
Zotero 插件